MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
Myomo Accounts Receivables 2011-2026 | MYO
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Myomo
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.1 M | 3.83 M | 1.9 M | 1.96 M | 925 K | 424 K | 382 K | 297 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.1 M | 297 K | 1.73 M |
Quarterly Accounts Receivables Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.29 M | 7.05 M | 4.66 M | 3.83 M | 3.73 M | 2.53 M | 1.68 M | 2.38 M | 2.52 M | 1.64 M | 1.55 M | 1.9 M | 1.6 M | - | 1.69 M | 1.96 M | 2.22 M | 1.13 M | 765 K | 925 K | 925 K | 925 K | 925 K | 424 K | 424 K | 424 K | 424 K | 382 K | 382 K | 382 K | 382 K | 297 K | 297 K | 297 K | 297 K | 115 K | 115 K | 115 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.05 M | 115 K | 1.53 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
17.9 M | $ 3.71 | -5.12 % | $ 138 M |  France |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B |  USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 9.2 | 2.45 % | $ 330 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 37.08 | 1.42 % | $ 1.15 B | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.66 | -0.16 % | $ 208 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.16 | 7.46 % | $ 1.31 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.55 | 0.1 % | $ 735 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.42 | 1.58 % | $ 171 M | USA |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.33 | -1.85 % | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
13.7 M | $ 101.78 | 0.8 % | $ 1.29 B | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.67 | -3.52 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
128 K | $ 2.32 | 7.41 % | $ 3.62 M | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 63.3 | 1.44 % | $ 3.45 B |  Britain |
 |
InspireMD
NSPR
|
2.17 M | $ 1.77 | -1.12 % | $ 114 M |  Israel |
 |
LENSAR
LNSR
|
6.08 M | $ 5.58 | 0.36 % | $ 64.3 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 11.39 | -0.78 % | $ 1.54 B | USA |
 |
Penumbra
PEN
|
190 M | $ 336.27 | 0.63 % | $ 13.1 B | USA |
 |
Medtronic PLC
MDT
|
6.52 B | $ 87.89 | 1.51 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
75.7 M | $ 4.1 | -0.73 % | $ 606 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
112 K | $ 2.29 | -4.58 % | $ 134 M | Israel |
 |
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 16.23 | 2.01 % | $ 381 M | USA |
 |
NanoVibronix
NAOV
|
98 K | - | - | $ 1.08 M | USA |
 |
Inspire Medical Systems
INSP
|
120 M | $ 51.41 | -1.27 % | $ 1.51 B | USA |
 |
Orthofix Medical
OFIX
|
136 M | $ 11.93 | 1.79 % | $ 472 M |  Curacao |